Predictive therapeutic marker of bevacizumab against patients with ovarian cancer

JRCT ID: jRCT1031180427

Registered date:25/03/2019

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Advanced ovarian cancer
• Date of first enrollment: 24/06/2016
• Target sample size: 25
• Study type: Interventional
• Intervention(s): All patients undergo FDG-PET/MRI before and 4 weeks after initiation of bevacizumab therapy.

Outcome(s)

Primary Outcome

Changing of SUVmax, MTV and TLG, and the efficacy of bevacizumab
Evaluation after 1 month from administ ration of bevacizumab
Exploratory investigation of many biomarkers using blood sample

Key inclusion & exclusion criteria

• Age minimum: 20age
• Age maximum: Not applicable
• Gender: Female

Include criteria

1) Pathologically confirmed advanced ovarian cancer with stage III/IV
2) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
3) Patient with evaluable lesion based on RECIST
4) Written informed consent

Exclude criteria

1) Pregnant woman
2) Patients with double primary cancer or serious infectious disease requiring antibiotic therapy
3) Other cases attending physician it is determined unsuitable for registration of the study

Related Information

• Primary Sponsor: Hirakawa Takashi
• Secondary ID(s): UMIN000022481